Company Abercade presents a survey of the Russian market of vaccines used in viral hepatitis prevention for the period of 2005-2013 and the market forecast up to 2018.
The report contains:
- 28 pages
- 18 tables
- 13 diagrams
As reported by Abercade analysts, the period from 2005-2008 is characterized by a sustainable growth of the market of Hepatitis B vaccines. This trend is associated with the launch of the National Project “Health” (2006), in particular, its subprograms “Viral Hepatitis” and “Preventive Vaccination” (2007). In 2009 the responsibilities for purchasing HBV vaccines were delegated to Rospotrebnadzor (the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing). And as a result of Rospotrebnadzor recommendations to purchase serotype “ay” vaccine (the most common HBV serotype within the RF territory) and inability of Russian producers to satisfy completely the followed demand, a reduction of the market volume to 24.4 mln of adult doses was reported in 2009.
Since in 2009 the requirements for vaccines were not met and due to the additional vaccination of the population in 2010, the market growth reached almost 100% vs. 2009. However, as soon as responsibilities for procurement were assigned to the RF Ministry of Health and Social Development (2010), the Ministry has revised approaches to vaccine purchases in 2011-2013, the market volumes declined almost by 70%.